A Microsimulation Study of the Cost-Effectiveness of Hepatitis C Virus Screening Frequencies in Hemodialysis Centers
Journal of the American Society of Nephrology · 2023
DOI: 10.1681/asn.2022030245 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Society of Nephrology, 2023. Verfasst von Rachel L Epstein und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Section of Infectious Diseases, Boston University School of Medicine, Boston, Massachusetts. Hauptthemen laut MEDLINE: Hepatitis C, Hepatitis C, Chronic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Significance Statement Studies examining the cost-effectiveness of hepatitis C virus (HCV) screening methods or frequencies are lacking. The authors examined the cost-effectiveness of the Kidney Disease Improving Global Outcomes (KDIGO) 2018 guidelines' recommendation to test in-center hemodialysis patients for HCV every 6 months. They demonstrated that with current HCV prevalence, incidence, and treatment practices in patients receiving hemodialysis, screening for HCV every 6 months is not cost-effective under a willingness-to-pay threshold of US$150,000, even if baseline survival rates doubled or all patients received treatment on diagnosis. Screening only at dialysis initiation or every 2 years are cost-effective approaches, however, with incremental cost-effectiveness ratios of $82,739 and $140,193, respectively, per quality-adjusted life-year saved compared with no screening. These data suggest that reevaluation of HCV screening guidelines in hemodialysis patients should be considered.
Background
National guidelines recommend twice-yearly hepatitis C virus (HCV) screening for patients receiving in-center hemodialysis. However, studies examining the cost-effectiveness of HCV screening methods or frequencies are lacking.
Methods
We populated an HCV screening, treatment, and disease microsimulation model with a cohort representative of the US in-center hemodialysis population. Clinical outcomes, costs, and cost-effectiveness of the Kidney Disease Improving Global Outcomes (KDIGO) 2018 guidelines–endorsed HCV screening frequency (every 6 months) were compared with less frequent periodic screening (yearly, every 2 years), screening only at hemodialysis initiation, and no screening. We estimated expected quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs) between each screening strategy and the next less expensive alternative strategy, from a health care sector perspective, in 2019 US dollars. For each strategy, we modeled an HCV outbreak occurring in 1% of centers. In sensitivity analyses, we varied mortality, linkage to HCV cure, screening method (ribonucleic acid versus antibody testing), test sensitivity, HCV infection rates, and outbreak frequencies.
Results
Screening only at hemodialysis initiation yielded HCV cure rates of 79%, with an ICER of $82,739 per QALY saved compared with no testing. Compared with screening at hemodialysis entry only, screening every 2 years increased cure rates to 88% and decreased liver-related deaths by 52%, with an ICER of $140,193. Screening every 6 months had an ICER of $934,757; in sensitivity analyses using a willingness-to-pay threshold of $150,000 per QALY gained, screening every 6 months was never cost-effective.
Conclusions
The KDIGO-recommended HCV screening interval (every 6 months) does not seem to be a cost-effective use of health care resources, suggesting that re-evaluation of less-frequent screening strategies should be considered.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Section of Infectious Diseases, Boston University School of Medicine, Boston, Massachusetts.
- Department of Pediatrics, Section of Infectious Diseases, Boston University School of Medicine, Boston, Massachusetts.
- Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts.
- Department of Medicine, Renal-Electrolyte Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
- Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania.
- Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts.
Förderung
- NIDA NIH HHS
- NIAID NIH HHS
Zitieren
APA
Epstein, R. L., Pramanick, T., Baptiste, D., Buzzee, B., Reese, P. P., Linas, B. P., & Sawinski, D. (2023). A Microsimulation Study of the Cost-Effectiveness of Hepatitis C Virus Screening Frequencies in Hemodialysis Centers. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2022030245
Vancouver
Epstein RL, Pramanick T, Baptiste D, Buzzee B, Reese PP, Linas BP, et al. A Microsimulation Study of the Cost-Effectiveness of Hepatitis C Virus Screening Frequencies in Hemodialysis Centers. Journal of the American Society of Nephrology. 2023. doi:10.1681/asn.2022030245
BibTeX
@article{Epstein2023,
author = {Epstein, Rachel L and Pramanick, Tannishtha and Baptiste, Dimitri and Buzzee, Benjamin and Reese, Peter P and Linas, Benjamin P and Sawinski, Deirdre},
title = {A Microsimulation Study of the Cost-Effectiveness of Hepatitis C Virus Screening Frequencies in Hemodialysis Centers},
journal = {Journal of the American Society of Nephrology},
year = {2023},
doi = {10.1681/asn.2022030245}
}
EUVIMED